Cargando…
Tumour necrosis factor in man: clinical and biological observations.
Eighteen patients with advanced cancer have been treated intravenously with human recombinant tumour necrosis factor (rhTNF). The drug produced febrile reactions at all doses although these were preventable by steroids and indomethacin. Doses at or above 9 x 10(5) units (400 micrograms)m-2 were asso...
Autores principales: | Selby, P., Hobbs, S., Viner, C., Jackson, E., Jones, A., Newell, D., Calvert, A. H., McElwain, T., Fearon, K., Humphreys, J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1987
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002406/ https://www.ncbi.nlm.nih.gov/pubmed/3435706 |
Ejemplares similares
-
Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.
por: Jones, A. L., et al.
Publicado: (1990) -
Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
por: Selby, P. J., et al.
Publicado: (1987) -
Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.
por: Forgeson, G. V., et al.
Publicado: (1988) -
Childhood rhabdomyosarcoma: experience of the Children's Solid Tumour Group.
por: Kingston, J. E., et al.
Publicado: (1983) -
Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.
por: Perren, T. J., et al.
Publicado: (1990)